Information  X 
Enter a valid email address

Verseon Corporation (VERS)

  Print      Mail a friend

Wednesday 03 July, 2019

Verseon Corporation

Additional Listing & Total Voting Rights

RNS Number : 2760E
Verseon Corporation
03 July 2019
 

July 3, 2019

Verseon Corporation

("Verseon" or the "Company")

Additional Listing & Total Voting Rights

Fremont, Calif.-Verseon, a technology-based pharmaceutical company, announces that application has been made for 8,476 new shares of common stock ("Common Shares") of par value $0.001 each to be admitted to trading on AIM pursuant to regularly scheduled vesting of restricted stock units (the "Issuance").

The 8,476 Common Shares were issued to Dr. Hecht, a non-executive Directors of the Company, in relation to the payment of his Director's fees. Following the Issuance, Dr. Hecht will hold 115,370 Common Shares, representing 0.07% of the Company's issued share capital.

The 8,476 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on July 8, 2019 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 159,737,905 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 159,694,988. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

For further information, please contact

Verseon Corporation

www.verseon.com

Sebastian Wykeham / Tina Schlafly

+1 (510) 225 9000

Arden Partners (NOMAD and Joint Broker)

 

Ruari McGirr / Ciaran Walsh/ Dan Gee-Summons (Corporate Finance) / Fraser Marshall (Equity Sales)

+44 (0) 20 7614 5900

Cantor Fitzgerald Europe (Joint Broker) 

 

Phil Davies

+44 (0) 20 7894 7000

 

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisers)

 

Henry Harrison-Topham / Jamie Hooper

+44 (0) 20 7466 5000

 

For trade and pharma media enquiries, please contact

Vane Percy & Roberts

 

Simon Vane Percy

+44 (0) 1737 821 890

 

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

 

Dr. Thomas Hecht

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Chairman

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Verseon Corporation

b)

 

LEI

 

 

213800CB2DUHDL6EPW12

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Restricted stock grant of Common Shares of par value $0.001

 

ISIN: USU9221J1171

 

 

 

b)

 

Nature of the transaction

 

 

Vesting of restricted stock units

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

Nil

8,476

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

 

- Price

 

 

 

8,476

 

 

-

e)

 

Date of the transaction

 

 

30 June 2019

f)

 

Place of the transaction

 

 

N/a

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCEAPXAEAENEFF

a d v e r t i s e m e n t